ECSP034708A - Nueva sal de benzoilguanidina - Google Patents

Nueva sal de benzoilguanidina

Info

Publication number
ECSP034708A
ECSP034708A EC2003004708A ECSP034708A ECSP034708A EC SP034708 A ECSP034708 A EC SP034708A EC 2003004708 A EC2003004708 A EC 2003004708A EC SP034708 A ECSP034708 A EC SP034708A EC SP034708 A ECSP034708 A EC SP034708A
Authority
EC
Ecuador
Prior art keywords
benzoilguanidina
salt
new
trifluoromrtylbenzoylguanidine
pyrrolylcarbonyl
Prior art date
Application number
EC2003004708A
Other languages
English (en)
Inventor
Werner Rall
Peter Sieger
Christian Eickmeier
Rolf Herter
Volkmar Koerner
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP034708A publication Critical patent/ECSP034708A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El invento se refiere al hidrocloruro de 4-[4-(2-pirrolilcarbonil)]-3-trifluoromrtilbenzoilguanidina, procedimientos para la preparación de un medicamento
EC2003004708A 2001-02-15 2003-07-29 Nueva sal de benzoilguanidina ECSP034708A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10106970A DE10106970A1 (de) 2001-02-15 2001-02-15 Neues Benzoylguanidinsalz

Publications (1)

Publication Number Publication Date
ECSP034708A true ECSP034708A (es) 2003-12-24

Family

ID=7674094

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004708A ECSP034708A (es) 2001-02-15 2003-07-29 Nueva sal de benzoilguanidina

Country Status (31)

Country Link
US (2) US20080025919A1 (es)
EP (1) EP1362030B1 (es)
JP (3) JP4408626B2 (es)
KR (1) KR100862176B1 (es)
CN (1) CN1222510C (es)
AT (1) ATE553078T1 (es)
AU (1) AU2002250939B2 (es)
BG (1) BG66330B1 (es)
BR (1) BR0207867A (es)
CA (1) CA2434829C (es)
CY (1) CY1112878T1 (es)
CZ (1) CZ303277B6 (es)
DE (1) DE10106970A1 (es)
DK (1) DK1362030T3 (es)
EA (1) EA006245B1 (es)
EC (1) ECSP034708A (es)
EE (1) EE200300393A (es)
ES (1) ES2385472T3 (es)
HR (1) HRP20030653B1 (es)
HU (1) HU230035B1 (es)
IL (1) IL156934A (es)
NO (1) NO20033299D0 (es)
NZ (1) NZ528081A (es)
PL (1) PL213300B1 (es)
PT (1) PT1362030E (es)
RS (1) RS52014B (es)
SI (1) SI1362030T1 (es)
SK (1) SK287830B6 (es)
UA (1) UA74625C2 (es)
WO (1) WO2002064563A1 (es)
ZA (1) ZA200305365B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
DE10144030A1 (de) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
JP2011527677A (ja) * 2008-07-08 2011-11-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎｈｅ−１阻害剤として有用なピロリジニル及びピペリジニル化合物
US10405746B2 (en) * 2014-04-14 2019-09-10 The University Of Memphis Research Foundation Wireless analog passive sensors
US12369831B1 (en) 2018-04-30 2025-07-29 Bashir I. Morshed Apparatus and method to capture body signals with conjugate coils and paired coils

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
DE19843489B4 (de) * 1998-09-22 2006-12-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung
US6323207B1 (en) * 1998-09-22 2001-11-27 Boehringer Ingelheim Pharma Kg Benzoylguanidine derivatives
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof

Also Published As

Publication number Publication date
PT1362030E (pt) 2012-07-04
PL362129A1 (en) 2004-10-18
CN1491213A (zh) 2004-04-21
CA2434829C (en) 2009-12-08
KR20030075197A (ko) 2003-09-22
PL213300B1 (pl) 2013-02-28
RS52014B (sr) 2012-04-30
NO20033299L (no) 2003-07-22
JP2004518721A (ja) 2004-06-24
WO2002064563A1 (de) 2002-08-22
ES2385472T3 (es) 2012-07-25
CZ303277B6 (cs) 2012-07-11
HK1064093A1 (zh) 2005-01-21
HUP0303027A3 (en) 2010-04-28
JP4408626B2 (ja) 2010-02-03
BR0207867A (pt) 2004-03-23
BG108065A (bg) 2005-01-31
HUP0303027A2 (hu) 2003-12-29
CN1222510C (zh) 2005-10-12
EA006245B1 (ru) 2005-10-27
HRP20030653A2 (en) 2005-06-30
KR100862176B1 (ko) 2008-10-09
ATE553078T1 (de) 2012-04-15
JP5745215B2 (ja) 2015-07-08
EE200300393A (et) 2003-12-15
CY1112878T1 (el) 2016-04-13
JP2009235097A (ja) 2009-10-15
EP1362030A1 (de) 2003-11-19
UA74625C2 (en) 2006-01-16
BG66330B1 (bg) 2013-06-28
YU61503A (sh) 2006-05-25
EP1362030B1 (de) 2012-04-11
IL156934A (en) 2005-12-18
HU230035B1 (hu) 2015-05-28
SI1362030T1 (sl) 2012-07-31
EA200300771A1 (ru) 2004-02-26
DE10106970A1 (de) 2002-08-29
NZ528081A (en) 2005-10-28
HRP20030653B1 (en) 2012-06-30
DK1362030T3 (da) 2012-07-09
SK10202003A3 (sk) 2004-02-03
ZA200305365B (en) 2004-04-22
NO20033299D0 (no) 2003-07-22
AU2002250939B2 (en) 2007-09-06
US20080025919A1 (en) 2008-01-31
JP2013107906A (ja) 2013-06-06
CA2434829A1 (en) 2002-08-22
CZ20032210A3 (cs) 2003-12-17
SK287830B6 (sk) 2011-11-04
IL156934A0 (en) 2004-02-08
US20080241077A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
ATE402945T1 (de) Neuer steroidagonist für fxr
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
ATE440603T1 (de) 8-hydroxychinolinderivate
DK1749818T3 (da) Phenylpiperidinderivater som serotoningenoptagelseshæmmere
UY26754A1 (es) Derivados de la 1, 3, 8, -triaza-spiro (4,5) decan-4-ona
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
DK1585743T3 (da) 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
DK1694318T3 (da) (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
ATE399770T1 (de) Tachykininrezeptorantagonisten
ATE308522T1 (de) Opioidrezeptorantagonisten
MY151229A (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
MXPA05013758A (es) Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas.
DE60225694D1 (de) Fexofenadine hydrochlorid polymorph
ECSP034708A (es) Nueva sal de benzoilguanidina
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
DK1301475T3 (da) Arylsulfonamider, som serotoninantagonist til behandling af obesitet
DK1861360T3 (da) Pyrrolidin-derivater som histamin-H3-receptorantagonister
DK1368336T3 (da) Thiophensubstituerede aminderivater som GlyT-1-inhibitorer
DK1585728T3 (da) Iminosyrederivater som inhibitorer af matrix-metalloproteinaser
ATE382607T1 (de) Antitrombotische aether